Key regions: Germany, South Korea, France, United States, United Kingdom
The Anti-Coagulants market in Pakistan has been growing steadily over the years, with an increasing demand for these drugs in the country.
Customer preferences: Anti-coagulants are primarily used to prevent blood clots or to treat existing blood clots. The demand for these drugs is driven by a growing prevalence of cardiovascular diseases, such as deep vein thrombosis, pulmonary embolism, and stroke. Patients with these conditions require long-term treatment with anti-coagulants to prevent further complications. In addition, the aging population in Pakistan is also contributing to the growing demand for these drugs.
Trends in the market: One of the major trends in the Anti-Coagulants market in Pakistan is the shift towards newer oral anti-coagulants, which are more effective and have fewer side effects compared to traditional anti-coagulants like Warfarin. These newer drugs have been gaining popularity among patients and healthcare professionals in the country. Another trend is the increasing use of anti-coagulants in the treatment of cancer-related blood clots.
Local special circumstances: Pakistan has a high burden of cardiovascular diseases, with an estimated 30% of the population suffering from hypertension. This has led to an increasing demand for anti-coagulants in the country. In addition, the country has a large aging population, which is also contributing to the growing demand for these drugs. However, the high cost of newer oral anti-coagulants may limit their accessibility to a large portion of the population.
Underlying macroeconomic factors: The healthcare sector in Pakistan is growing, with increasing investments in healthcare infrastructure and facilities. The government has also launched several initiatives to improve access to healthcare services in the country. However, the healthcare system in Pakistan is still facing several challenges, including a shortage of healthcare professionals, inadequate healthcare facilities in rural areas, and a lack of health insurance coverage for a large portion of the population. These factors may impact the accessibility and affordability of anti-coagulants in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
